ClinicalTrials.gg
Active, not recruitingNCT03006068U-ACTIVATEUpdated Jan 12, 2026

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

A Phase 3 interventional study of Upadacitinib (ABT-494) and Placebo in Ulcerative Colitis (UC), sponsored by AbbVie. Active, not recruiting at 492 sites in 46 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
950
Allocation
Non-randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing upadacitinib in Colitis, Ulcerative — 8 open to participants now, 10 under way, 3 of them phase 3. upadacitinib · Colitis, Ulcerative.

Planned enrollment
2nd of 12
950 · median 180
Started
2017
the only one that year
Phase 3
4 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
4 of 12
AbbVie

Among the 12 studies testing upadacitinib in Colitis, Ulcerative, this one is the 2nd largest by planned enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

8 of the 12 studies testing upadacitinib in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing upadacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • Ulcerative Colitis (UC)
  • Upadacitinib (ABT-494)
  • Long Term Extension (LTE)
  • Safety
  • Efficacy
  • RINVOQ
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Note: Participants aged 16 or 17 may enroll in M14-234 or M14-675 where locally permissible

  • Participant has not achieved clinical response at the end of the induction period (Week 8) in Study M14-234 Substudy 1, has had loss of response during the maintenance period of Study M14-234 Substudy 3, or has successfully completed Study M14-234 Substudy 3. During the COVID-19 pandemic, for participants with missing endoscopy at Week 8, Week 16 or Week 52 due to the COVID-19 pandemic in Studies M14-234 Substudy 2, M14-234 Substudy 3 and M14-675, participants may be enrolled if certain criteria are met.
  • If female, participant must meet the criteria.
  • Women of must have a negative urine pregnancy test at Week 0 visit.
  • Participant is judged to be in otherwise good health as determined by the principal investigator based upon clinical evaluations performed during the preceding study (Study M14-234).
  • Must be able and willing to give written and to comply with the requirements of this study protocol.

Exclusion criteria

Exclusion Criteria:

  • For any reason participant is considered by the investigator to be an unsuitable candidate.
  • Female participant with a positive pregnancy test at the final visit of Study M14-234 or who is considering becoming pregnant during the study or within 30 days after the last dose of study drug.
  • Known to upadacitinib or its or had any adverse event (AE) during the preceding studies, that in the investigator's judgment makes the participant unsuitable for this study.
  • Participant with an active or recurrent infection that based on the investigator's clinical assessment makes the participant an unsuitable candidate for the study. Participants with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection has been successfully treated.
  • Current evidence of active tuberculosis (TB); current evidence of latent tuberculosis and for any reason the participant cannot take full course of TB prophylaxis treatment as required per protocol.
  • Participant with a poorly controlled medical condition, such as uncontrolled diabetes, unstable ischemic heart disease, moderate or severe congestive heart failure ( class III or IV), recent cerebrovascular accidents and any other condition which, in the opinion of the investigator or sponsor, would put the subject at risk by participation in this study.
  • Participants have , high-grade dysplasia, un-removed low-grade dysplasia of the gastrointestinal tract diagnosed at the endoscopy performed at the final visit of Study M14-234.
  • History of any malignancy except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix from evaluations performed in Study M14-234.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
950 participants (estimated)

Study arms

  • Experimental
    Participants receiving Upadacitinib (ABT-494) Dose A

    The participants in this arm will receive Upadacitinib (ABT-494) dose A.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Participants receiving Upadacitinib (ABT-494) Dose B

    The participants in this arm will receive Upadacitinib (ABT-494) dose B.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Participants receiving Upadacitinib (ABT-494) Dose A or Dose B

    The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Participants receiving Placebo

    The participants in this arm will receive placebo until study is unblinded.

    Drug: Placebo

  • Experimental
    Participants receiving Upadacitinib (ABT-494) Dose C

    The participants in this arm will receive Upadacitinib (ABT-494) dose C.

    Drug: Upadacitinib (ABT-494)

Interventions

  • Upadacitinib (ABT-494) will be administered orally.

    Also known as: RINVOQ

  • DrugPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Assessing Treatment-Emergent Adverse Events

    Treatment-emergent adverse events are defined as events that begin or worsen either on or after the first dose of the study drug and within 30 days after the last dose of the study drug in the analysis period.

    Time frame: Up to 288 Weeks

07

Study locations

492 sites
  • East View Medical Research, LLC /ID# 171184
    Mobile, Alabama 36606, United States
  • CB Flock Research Corporation /ID# 165986
    Mobile, Alabama 36608, United States
  • Delsol Research Management, Ll /Id# 170130
    Chandler, Arizona 85224, United States
  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211886
    Mesa, Arizona 85206, United States
  • Duplicate_Arizona Arthritis & Rheumatology Research, PLLC /ID# 169823
    Sun City, Arizona 85306, United States
  • Adobe Clinical Research LLC /ID# 155249
    Tucson, Arizona 85712, United States
  • Duplicate_University of Arizona /ID# 150568
    Tucson, Arizona 85724, United States
  • Citrus Valley Gastroenterology /ID# 151915
    Covina, California 91722-3797, United States
  • Newport Huntington Medical Group /ID# 217006
    Huntington Beach, California 92648-5994, United States
  • UC San Diego Health System /ID# 155187
    La Jolla, California 92037, United States
  • United Medical Doctors /ID# 207467
    Los Alamitos, California 90720-3309, United States
  • TLC Clinical Research Inc /ID# 216830
    Los Angeles, California 90048, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 157082
    Los Angeles, California 90067-2001, United States
  • Facey Medical Foundation /ID# 203135
    Mission Hills, California 91345, United States
  • United Medical Doctors - Murrieta /ID# 151213
    Murrieta, California 92563, United States
  • Ventura County Gastroenterology Medical Group /ID# 163417
    Oxnard, California 93030-0190, United States
  • Inland Empire Clinical Trials, LLC /ID# 216163
    Rialto, California 92377, United States
  • San Diego Clinical Trials /ID# 212121
    San Diego, California 92120, United States
  • Medical Assoc Research Grp /ID# 169149
    San Diego, California 92123, United States
  • Univ of California San Francis /ID# 164583
    San Francisco, California 94158, United States
  • Delta Waves, Inc. /ID# 151727
    Colorado Springs, Colorado 80918, United States
  • South Denver Gastroenterology /ID# 151224
    Lone Tree, Colorado 80124, United States
  • Western States Clinical Res /ID# 158078
    Wheat Ridge, Colorado 80033-2896, United States
  • Duplicate_Western Connecticut Medical Group /ID# 169211
    Danbury, Connecticut 06810, United States
  • Gastroenterology Center of Connecticut /ID# 150534
    Hamden, Connecticut 06518, United States
  • West Central Gastroenterology /ID# 155242
    Clearwater, Florida 33762, United States
  • Moonshine Research Center, Inc /ID# 152534
    Doral, Florida 33166, United States
  • Universal Axon Clinical Research /ID# 213463
    Doral, Florida 33166, United States
  • Palmetto Research, LLC /ID# 151724
    Hialeah, Florida 33016, United States
  • Nature Coast Clinical Research - Inverness /ID# 154070
    Inverness, Florida 34452-4717, United States
  • Encore Borland-Groover Clinical Research /Id# 170913
    Jacksonville, Florida 32256, United States
  • SIH Research Mumtaz, Inc /ID# 163199
    Kissimmee, Florida 34741-4161, United States
  • Cfagi Llc /Id# 202018
    Maitland, Florida 32751-6108, United States
  • Duplicate_University of Miami /ID# 215443
    Miami, Florida 33136, United States
  • Advanced Pharma CR, LLC /ID# 151723
    Miami, Florida 33147, United States
  • New Horizon Research Center /ID# 152475
    Miami, Florida 33165-3372, United States
  • Crystal Pharmacology Research /ID# 151848
    Miami, Florida 33165, United States
  • Coral Research Clinic /ID# 150524
    Miami, Florida 33186-4643, United States
  • Advanced Research Institute, Inc /ID# 163093
    New Port Richey, Florida 34653, United States
  • Endoscopic Research, Inc. /ID# 151725
    Orlando, Florida 32803, United States
  • Omega Research Group /ID# 200271
    Orlando, Florida 32808, United States
  • Clinical Research Trials of Florida, Inc. /ID# 201791
    Tampa, Florida 33607, United States
  • Duplicate_University of South Florida /ID# 214494
    Tampa, Florida 33612, United States
  • Duplicate_AdventHealth Tampa /ID# 200274
    Tampa, Florida 33613-4680, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 165783
    Macon, Georgia 31201, United States
  • Infinite Clinical Trials /ID# 215342
    Riverdale, Georgia 30274, United States
  • Atlanta Gastroenterology Spec /ID# 150565
    Suwanee, Georgia 30024, United States
  • Next Innovative Clinical Research - Chicago /ID# 217323
    Chicago, Illinois 60605-2168, United States
  • Duplicate_The University of Chicago DCAM /ID# 150564
    Chicago, Illinois 60637, United States
  • Duplicate_NorthShore University HealthSystem /ID# 150570
    Evanston, Illinois 60201, United States
  • Northwest Health Care Associates /ID# 151591
    Hoffman Estates, Illinois 60169, United States
  • Carle Foundation Hospital /ID# 151155
    Urbana, Illinois 61801, United States
  • MediSphere Medical Research Center /ID# 152080
    Evansville, Indiana 47714-8011, United States
  • Indianapolis Gastroenterology /ID# 162914
    Indianapolis, Indiana 46237, United States
  • University of Iowa Hospitals and Clinics /ID# 157059
    Iowa City, Iowa 52242, United States
  • Cotton O'Neil Clinical Research Center, Digestive Health /ID# 167183
    Topeka, Kansas 66606, United States
  • Tri-State Gastroenterology /ID# 169812
    Crestview Hills, Kentucky 41017, United States
  • Houma Digestive Health Special /ID# 151851
    Houma, Louisiana 70360, United States
  • Nola Research Works, LLC /ID# 153365
    New Orleans, Louisiana 70115, United States
  • Louisiana Research Center, LLC /ID# 150526
    Shreveport, Louisiana 71105-6800, United States
  • University of Maryland, Baltimore /ID# 150529
    Baltimore, Maryland 21201, United States
  • Gastro Center of Maryland /ID# 200024
    Columbia, Maryland 21045, United States
  • Massachusetts General Hospital /ID# 165678
    Boston, Massachusetts 02114, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 151158
    Ann Arbor, Michigan 48109, United States
  • Huron Gastroenterology Assoc /ID# 152712
    Ann Arbor, Michigan 48197, United States
  • Clin Res Inst of Michigan, LLC /ID# 153031
    Chesterfield, Michigan 48047, United States
  • Clin Res Inst of Michigan, LLC /ID# 161983
    Chesterfield, Michigan 48047, United States
  • Revival Research Institute, LLC /ID# 207281
    Southfield, Michigan 48034-1659, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 157487
    Wyoming, Michigan 49519, United States
  • Mayo Clinic - Rochester /ID# 151681
    Rochester, Minnesota 55905-0001, United States
  • Minnesota Gastroenterology PA /ID# 151682
    Saint Paul, Minnesota 55114, United States
  • University of Mississippi Medical Center /ID# 213140
    Jackson, Mississippi 39216-4500, United States
  • Southern Therapy and Advanced Research (STAR) LLC /ID# 170713
    Jackson, Mississippi 39216, United States
  • Washington University-School of Medicine /ID# 150537
    St Louis, Missouri 63110, United States
  • Vector Clinical Trials /ID# 153052
    Las Vegas, Nevada 89128, United States
  • Dartmouth-Hitchcock Medical Center /ID# 150566
    Lebanon, New Hampshire 03756, United States
  • Cooper Gastroenterology at Fire Road /ID# 153048
    Egg Harbor, New Jersey 08234, United States
  • Atlantic Digestive Health Inst /ID# 150527
    Morristown, New Jersey 07960, United States
  • Rutgers Robert Wood Johnson /ID# 155247
    New Brunswick, New Jersey 08901, United States
  • Duplicate_University of New Mexico Department of Internal Medicine /ID# 214399
    Albuquerque, New Mexico 87131, United States
  • NY Scientific /ID# 152708
    Brooklyn, New York 11235, United States
  • Duplicate_NYU Langone Long Island Clinical Research Association /ID# 155271
    Great Neck, New York 11021, United States
  • Columbia Univ Medical Center /ID# 163409
    New York, New York 10032-3725, United States
  • Duplicate_DiGiovanna Institute for Medical Education & Research /ID# 201534
    North Massapequa, New York 11758, United States
  • Premier Medical Group - GI Division /ID# 153366
    Poughkeepsie, New York 12601, United States
  • Gastoenterology Group of Rochester /ID# 151080
    Rochester, New York 14618-5703, United States
  • Richmond University Medical Center /ID# 201860
    Staten Island, New York 10310-1664, United States
  • Montefiore Medical Center - Moses Campus /ID# 150559
    The Bronx, New York 10467, United States
  • Advantage Clinical Trials /ID# 163940
    The Bronx, New York 10468, United States
  • Digestive Health Partners - Biltmore Office /ID# 167238
    Asheville, North Carolina 28801, United States
  • Atrium Health Carolinas Medical Center /ID# 157060
    Charlotte, North Carolina 28203, United States
  • Charlotte Gastroenterology and Hepatology, PLLC /ID# 150561
    Charlotte, North Carolina 28207, United States
  • Atlantic Gastroenterology Clinical Research /ID# 151901
    Greenville, North Carolina 27834, United States
  • Clinical Trials of America /ID# 153453
    Winston-Salem, North Carolina 27103, United States
  • Duplicate_Atrium Health Wake Forest Baptist Medical Center /ID# 150528
    Winston-Salem, North Carolina 27157-0001, United States
  • Plains Clinical Research Center, LLC /ID# 170291
    Fargo, North Dakota 58104-5925, United States
  • Gastro Health Research /ID# 151683
    Cincinnati, Ohio 45219, United States
  • University Of Cincinnati Medical Center /ID# 164584
    Cincinnati, Ohio 45219, United States
  • The Ohio State University /ID# 169417
    Columbus, Ohio 43210, United States
  • Optimed Research, Ltd. /ID# 169697
    Columbus, Ohio 43235, United States

Showing the first 100 of 492 sites across 46 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Panaccione R, Panes J, Peyrin-Biroulet L, Colombel JF, Lindsay JO, Baert F, Atreya R, Vermeire S, Fujii T, Dubcenco E, Klaff J, Duncan B, Suravaram S, Fish I, Lacerda AP, Vladea R, Ford S, Shah S, Anyanwu SI, Rubin DT. Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clin Gastroenterol Hepatol. 2026 Feb 27:S1542-3565(26)00145-X. doi: 10.1016/j.cgh.2026.02.018. Online ahead of print. PubMed 41763462 ↗
  • Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S. Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):507-519. doi: 10.1016/S2468-1253(25)00017-2. PubMed 40347957 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Jul 2027, 126 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 126 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2016
First posted
Dec 30, 2016
StartActual
Jan 31, 2017
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03006068
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
Jan 31, 2017
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion